TumorSight Viz

K243189

SimBioSys, Inc. · cleared 2024-10-25 · product code QIH · Radiology

Premarket evidence — what FDA accepted

Device typesamd
source quote (p.5)
The TumorSight system consists of proprietary software developed by SimBioSys, Inc. hosted on a cloud-based platform and accessed on an off-the-shelf computer.
Algorithmdeep learning algorithm
source quote (p.8)
The measurements generated from the device result directly from the segmentation methodology and are an inferred reflection of the performance of the deep learning algorithm.
Adaptive (vs locked)FDA source did not state this
PCCPFDA source did not state this
Cybersecurity addressedFDA source did not state this

Validation studies (1)

Reader study (MRMC)

n=217 cases · 7 site(s)

endpoints: Tumor Volume; Tumor-to-breast volume ratio; Tumor longest dimension; Tumor-to-nipple distance; Tumor-to-skin distance; Tumor-to-chest distance; Tumor center of mass; Volumetric Dice; Surface Dice

standards: ISO 14971

Reported performance (2 observations)

diceas written: “Volumetric Dice0.75CI ± 0.24
source quote (p.9)
0.75 ± 0.24
diceas written: “Surface Dice0.88CI ± 0.24
source quote (p.9)
0.88±0.24

Each value carries its own analysis unit and task — never compare or pool across devices. Source: 510(k) summary PDF.

Predicate network

Postmarket — what happened after clearance

0
recalls in product code, 24mo
3
MAUDE reports in code, 12mo
vs code's own 3-yr baseline
1
drift signals on this device
  • re_clearance

    The FDA AI/ML device list shows a newer 510(k) K251766 (decision 2025-07-08) from SimBioSys, Inc. for a matching device line ("TumorSight Viz") — a new clearance for the same line is a change event.

    first seen 2026-07-08 · k_number:K251766

Recall and MAUDE counts are product-code-level (reports aren't reliably attributable to one device). Signals are descriptive observables with sources — never a judgment that the device is unsafe or drifting. Snapshot 2026-07-08.

Reimbursement — how devices like this got paid

Not yet tracked — no payment pathway indexed for this clearance (the reimbursement corpus is a growing seed set).

RIGOR™ Precedent · public FDA/CMS data · descriptive decision-support, not regulatory or reimbursement advice. Share this page: radar.healthai.com/precedent/device/K243189